(Q36233987)

English

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thomas C. Smyrk

7

object named as

Thomas C Smyrk

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Steven R Alberts

1

object named as

Steven R Alberts

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Michelle R. Mahoney

4

object named as

Michelle R Mahoney

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Daniel J Sargent

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Suresh Nair

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Margaret Mooney

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Stephen N Thibodeau

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Frank A Sinicrope

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Emily Chan

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sharlene Gill

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Morton S Kahlenberg

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Anthony F Shields

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

James T Quesenberry

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Thomas A Webb

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gist H Farr

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Barbara A Pockaj

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Axel Grothey

17

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Richard M Goldberg

18

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 April 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

The Journal of the American Medical Association

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

307

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1383-1393

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Mechanisms of resistance to HER family targeting antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Review: Biological relevance of disseminated tumor cells in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

The biological properties of cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

A Multiple Testing Procedure for Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

1 October 2017

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

22 September 2018

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

22 September 2018

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

22 September 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442260

21 October 2018

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://pubmed.ncbi.nlm.nih.gov/22474202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

https://pubmed.ncbi.nlm.nih.gov/22474202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMA.2012.385

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36233987&oldid=1774076003"